Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2025 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate in September Investor Conferences

BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
September 03, 2025 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 29, 2025 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 25, 2025 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS)...
August 06, 2025 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 05, 2025 18:09 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 04, 2025 20:24 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 04, 2025 08:30 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in...
August 04, 2025 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on...
July 29, 2025 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results

BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...